TGen News & Press Releases

TGen News & Press Releases

Like priming a pump, changes in cells damaged by chronic lung disease can result in severe COVID-19

Posted Wednesday July 14, 2021

Results from a TGen-led international study suggest that SARS-CoV-2 takes advantage of genetic changes among patients with pre-existing lung diseases

TGen COVID-19 variant tracking program receives grant from Taiwan Semiconductor Manufacturing Co.

Posted Monday June 7, 2021

TSMC support accelerates TGen’s infectious-disease monitoring of COVID-19 and potential future pandemics

New study predicts changing Lyme disease habitat across the West Coast

Posted Tuesday March 16, 2021

Army of ‘citizen scientists’ collect more than 18,000 tick samples for analysis in study funded by Bay Area Lyme Foundation

TGen seeks help from Arizona dog and cat owners for COVID-19 study

Posted Wednesday March 10, 2021

Project builds on ‘One Health’ testing and disease surveillance collaborations in Arizona

Men, older adults and smokers are more prone to infection by SARS-CoV-2

Posted Wednesday March 3, 2021

Study provides answers to who and why COVID-19 poses increased risk and potential death among certain demographics

TGen-led study confirms cell-free DNA in urine as potential method for cancer detection

Posted Wednesday February 17, 2021

If successful, non-invasive method could transform detection and treatment outcomes

15-year-old TGen patient and NASA devotee prepares for Mars landing

Posted Tuesday February 16, 2021

Feb. 18 celebration hopes to raise $30,000 for TGen Center for Rare Childhood Disorders

TGen-NAU study results show COVID-19 virus triggers antibodies from previous coronavirus infections

Posted Tuesday January 19, 2021

Findings suggest that prior immune experience could affect the course of patient’s disease

TGen identifies gene that could explain disparity in COVID-19 effects

Posted Tuesday December 15, 2020

Comparative analysis of human and animal coronaviruses strains implicates miR1307

TGen, Avery Therapeutics collaboration studies mechanism of action in engineered heart tissue

Posted Monday October 5, 2020

TGen’s analysis of proteins and metabolites could pave the way for Avery Therapeutics to gain FDA approval of human clinical trials

Prev
[1]
2
3
4
Next

Media Contact

Steve Yozwiak
[email protected]
602-343-8704

Newsletter

News Archive

View Media Release Archive

OnCline

TGen is a partner with OncLive

2021 © All Rights Reserved TGen. Registered 501(c)(3). EIN: 75-3065445